Acadia Pharma (ACAD) Misses Q2 EPS by 14c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $22.60 +2.31%
Revenue Growth %: +12.1%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +12.1%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.63), $0.14 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $97 thousand versus the consensus estimate of $90 thousand.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
